Literature DB >> 32092395

Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor).

Y C Zhu1, S A Barat2, K Borroto-Esoda2, D Angulo2, S Chaturvedi1, V Chaturvedi3.   

Abstract

Entities:  

Year:  2020        PMID： 32092395     DOI： 10.1016/j.ijantimicag.2020.105922

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


× No keyword cloud information.
  11 in total

Review 1.  Emerging and future strategies in the management of recalcitrant Candida auris.

Authors:  Nihal Bandara; Lakshman Samaranayake
Journal:  Med Mycol       Date:  2022-03-17       Impact factor: 4.076

2.  Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents.

Authors:  Samantha E Jacobs; Jonathan L Jacobs; Emily K Dennis; Sarah Taimur; Meenakshi Rana; Dhruv Patel; Melissa Gitman; Gopi Patel; Sarah Schaefer; Kishore Iyer; Jang Moon; Victoria Adams; Polina Lerner; Thomas J Walsh; YanChun Zhu; Mohammed Rokebul Anower; Mayuri M Vaidya; Sudha Chaturvedi; Vishnu Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2022-06-30       Impact factor: 5.938

3.  Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.

Authors:  Martin Hoenigl; Rosanne Sprute; Amir Arastehfar; John R Perfect; Cornelia Lass-Flörl; Romuald Bellmann; Juergen Prattes; George R Thompson; Nathan P Wiederhold; Mohanad M Al Obaidi; Birgit Willinger; Maiken C Arendrup; Philipp Koehler; Matteo Oliverio; Matthias Egger; Ilan S Schwartz; Oliver A Cornely; Peter G Pappas; Robert Krause
Journal:  Expert Opin Investig Drugs       Date:  2022-06-15       Impact factor: 6.498

Review 4.  Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections.

Authors:  Mahmoud Ghannoum; Maiken Cavling Arendrup; Vishnu P Chaturvedi; Shawn R Lockhart; Thomas S McCormick; Sudha Chaturvedi; Elizabeth L Berkow; Deven Juneja; Bansidhar Tarai; Nkechi Azie; David Angulo; Thomas J Walsh
Journal:  Antibiotics (Basel)       Date:  2020-08-25

Review 5.  Candida auris: A Quick Review on Identification, Current Treatments, and Challenges.

Authors:  Lucia Černáková; Maryam Roudbary; Susana Brás; Silva Tafaj; Célia F Rodrigues
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

Review 6.  Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor.

Authors:  Sabelle Jallow; Nelesh P Govender
Journal:  J Fungi (Basel)       Date:  2021-02-25

Review 7.  Novel antifungal agents in clinical trials.

Authors:  Samantha E Jacobs; Panagiotis Zagaliotis; Thomas J Walsh
Journal:  F1000Res       Date:  2021-06-28

Review 8.  The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.

Authors:  Martin Hoenigl; Rosanne Sprute; Matthias Egger; Amir Arastehfar; Oliver A Cornely; Robert Krause; Cornelia Lass-Flörl; Juergen Prattes; Andrej Spec; George R Thompson; Nathan Wiederhold; Jeffrey D Jenks
Journal:  Drugs       Date:  2021-10-09       Impact factor: 9.546

Review 9.  Investigational Agents for the Treatment of Resistant Yeasts and Molds.

Authors:  Garret T Seiler; Luis Ostrosky-Zeichner
Journal:  Curr Fungal Infect Rep       Date:  2021-05-28

Review 10.  Promising Drug Candidates and New Strategies for Fighting against the Emerging Superbug Candida auris.

Authors:  Muriel Billamboz; Zeeshan Fatima; Saif Hameed; Samir Jawhara
Journal:  Microorganisms       Date:  2021-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.